Skip Navigation

Annals of Oncology 2006 17(Supplement 7):vii124-vii127; doi:10.1093/annonc/mdl964
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Caraglia, M.
Right arrow Articles by Tagliaferri, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caraglia, M.
Right arrow Articles by Tagliaferri, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Targeting Raf-kinase: molecular rationales and translational issues

M. Caraglia1, P. Tassone2, M. Marra1, A. Budillon1, S. Venuta2 and P. Tagliaferri2,*

1 National Cancer Institute Fondazione ‘G. Pascale’, Experimental Oncology Department, Experimental Pharmacology Unit, Naples; 2 Department of Experimental and Clinical Medicine, University Magna GrFormulacia of Catanzaro, Italy

* Correspondence to: P. Tagliaferri, Department of Experimental and Clinical Medicine, University Magna GrFormulacia of Catanzaro Via T. Campanella 115, 88100 Catanzaro, Italy. Tel: +39-0961-712385; Fax: +39-0961-770270; E-mail: tagliaferri{at}unicz.it

Target-based therapy has been a promising anti-cancer strategy in the preclinical setting, but its efficacy is still limited in clinical practice. The latter was probably due to the lack of identification of molecular targets in order to predict clinical response and for the existence of multiple survival compensatory downstream pathways. Therefore, the use of downstream targets could be useful in order to avoid these overcoming pathways. One of these targets is Raf-kinase. In this review we describe the structure and functions of the components of Raf-kinase family and their relevance in proliferation and survival of tumor cells. Moreover, we illustrate the signal transduction pathways regulated by Raf-kinases. The main preclinical and clinical results obtained with the use of the Raf-kinase inhibitor BAY 43-9006 or sorafenib are also described. The multi-target function of sorafenib is also explained and the disclosure of new therapeutic opportunities based on the dual inhibition of cancer proliferation and neo-angiogenesis is discussed. In conclusion, Raf-kinase appears an appealing therapeutic target, even it other preclinical and clinical studies are warranted in order to evaluate the activity of sorafenib both in monotherapy and in combination with other agents.

Key words: Raf-kinase, apoptosis, cancer therapy, BAY 43–9006, angiogenesis, VEGF-R


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.